Multiple large, peer‑reviewed studies published in 2026 add to a growing body of evidence that taking acetaminophen (Tylenol/paracetamol) during pregnancy is not linked to higher risks of autism, attention deficit hyperactivity disorder (ADHD), or intellectual disability in children.
Context and controversy
In 2025 a high‑profile review raised concerns about a possible association between prenatal acetaminophen use and neurodevelopmental outcomes. That prompted public debate and led regulators to update labeling to note a potential association. Medical societies and many experts pushed back, stressing that association is not the same as causation and warning that unclear messaging could harm pregnant people who rely on safe symptom control.
Key new studies
– JAMA Internal Medicine, June 2026 — A 20‑year cohort study from Hong Kong followed 708,020 mother–child pairs, roughly 43% of whom had prenatal acetaminophen exposure. The investigators used sibling‑matched analyses to reduce confounding by family factors and found no increased risk of autism or ADHD associated with prenatal acetaminophen. Results were consistent across timing of exposure, dosage, and use patterns.
– JAMA Pediatrics, April 2026 — A large Danish registry study looked at about 1.5 million children born from 1997 to 2022; 31,098 were recorded as exposed in utero. The observed rates of autism were not higher among exposed children (1.8% exposed versus 3% unexposed in the reported sample), and the lack of an association held after accounting for trimester of exposure, dosage, and other individual risk factors.
Other evidence
A rigorous systematic review and meta‑analysis considered available studies and found no convincing evidence that acetaminophen in pregnancy raises the risk of autism, ADHD, or intellectual disabilities. Taken together with the large new cohort studies, the evidence increasingly supports the position that prenatal acetaminophen use, when used as directed, is not a cause of these neurodevelopmental conditions.
Expert interpretation
Clinicians and professional organizations emphasize caution when interpreting observational data. Such studies can reveal associations but cannot prove causation, and they are often vulnerable to confounding factors that affect both medication use and developmental outcomes. The American College of Obstetricians and Gynecologists and other experts have emphasized that alarmist messages about acetaminophen and autism risk can be harmful and that the medication remains an important option during pregnancy for treating fever and pain when recommended by a health care provider.
Practical considerations
– Acetaminophen is one of the commonly recommended options for treating fever and pain in pregnancy; untreated fever and significant pain can themselves pose risks to pregnant people and developing fetuses.
– Some other pain relievers, for example NSAIDs like ibuprofen, have known risks in pregnancy and cross the placenta; they are handled differently in clinical guidance.
– Pregnant people should follow their clinician’s advice about medication choice, timing, and dosage.
Bottom line
Recent large, well‑designed studies published in established medical journals have found no evidence that prenatal acetaminophen use causes autism, ADHD, or intellectual disability. While research into prenatal exposures and neurodevelopment continues, current evidence supports the view that acetaminophen, used as directed under medical guidance, remains a safe option for treating pain and fever during pregnancy.
